⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 6, 2026Open Access

Correction: Wu et al. WIP1 Inhibition by GSK2830371 Potentiates HDM201 Through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells. Cancers 2021, 13, 3876

Wu CE Ahmed Khairallah Mahdi Chen-Yang Huang Chiao-Ping Chen Yi-Ru Pan John Wen-Cheng Chang Jen-Shi Chen Yeh CN John Lunec

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to investigate the effects of GSK2830371 on WIP1 inhibition and subsequent p53 activation in liver cancer cells.
Inhibition of WIP1 using GSK2830371
Analysis of p53 phosphorylation levels
Examination of cellular responses in liver adenocarcinoma cells
Increased p53 phosphorylation observed with GSK2830371 treatment
Enhanced activation of p53 leads to improved cellular response in liver cancer cells
Potential augmentation of cancer therapeutic strategies noted

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Correction reveals GSK2830371 boosts p53 activation in liver adenocarcinoma, indicating enhanced cancer treatment potential.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

CE et al. (2026) studied this question.

synapsesocial.com/papers/698827b40fc35cd7a884690e https://doi.org/10.3390/cancers18030530

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Abstract C030: The Wip1 phosphatase activator QGC-8-52 selectively sensitizes p53-deficient cancer cells to chemotherapy2024
2Abstract 328: Establishment of assay systems for drug development against the oncogenic phosphatase WIP1.Original Research · 2026
3The Synergistic Effect of Nutlin-3a and a Wip1 Inhibitor in Inducingp53 ActivityReview · 2026
4Correction: Huang et al. PAICS/DYRK3 Multienzyme Interactions as Coregulators of Purinosome Formation and Metabolism on Radioresistance in Oral Squamous Cell Carcinoma. Int. J. Mol. Sci. 2023, 24, 17346Original Research · 2026
5Wip1 Inhibition Enhances the Therapeutic Efficacy of Palbociclib in Luminal A Breast Cancer by Modulating Cell Cycle Progression and ApoptosisOriginal Research · 2026
6ID #1053 PPM1G is a PPM1D paralogue that modulates sensitivity to PPM1D inhibition in p53-competent diffuse midline gliomasOriginal Research · 2026
7WWP2-induced inhibition of hepatocellular carcinoma cellular senescence via the ubiquitination and degradation of p212025 · 2 citations
8Abstract 6762: A novel therapeutic approach for targeting p53-mutant cancers by leveraging DNA damage response vulnerabilitiesEarly-Phase Clinical Trial · 2026